{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:25Z","timestamp":1790419525583,"version":"4.1.0"},"reference-count":25,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,30]]},"DOI":"10.20945\/2359-3997000000222","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T13:37:02Z","timestamp":1586353022000},"source":"Crossref","is-referenced-by-count":4,"title":["A two-year follow-up of asfotase alfa replacement in a patient with hypophosphatasia: clinical, biochemical, and radiological evaluation"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8322-9000","authenticated-orcid":false,"given":"Fernanda Salles","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-2834","authenticated-orcid":false,"given":"D\u00e9bora Cristiane","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-0115","authenticated-orcid":false,"given":"Henrique Pierotti","family":"Arantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-8946","authenticated-orcid":false,"given":"Marise","family":"Lazaretti-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"4","key":"key20200408093659_B1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia-aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","unstructured":".Whyte MP. Hypophosphatasia-aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12(4):233-46.","journal-title":"Nat Rev Endocrinol"},{"key":"key20200408093659_B2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-62703-562-0_3","article-title":"Multisystemic functions of alkaline phosphatases","volume":"1053","author":"Buchet","year":"2013","unstructured":".Buchet R, Mill\u00e1n JL, Magne D. Multisystemic functions of alkaline phosphatases. Methods Mol Biol. 2013;1053:27-51.","journal-title":"Methods Mol Biol"},{"key":"key20200408093659_B3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.metabol.2017.08.013","article-title":"Hypophosphatasia","volume":"82","author":"Mornet","year":"2018","unstructured":".Mornet E. Hypophosphatasia. Metabolism. 2018;82:142-55.","journal-title":"Metabolism"},{"issue":"3","key":"key20200408093659_B4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-016-0309-0","article-title":"Hypophosphatasia","volume":"14","author":"Linglart","year":"2016","unstructured":".Linglart A, Biosse-Duplan M. Hypophosphatasia. Curr Osteoporos Rep. 2016;14(3):95-105.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"key20200408093659_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4274\/jcrpe.4426","article-title":"Could alerting physicians for low alkaline phosphatase levels be helpful in early diagnosis of hypophosphatasia?","volume":"10","author":"Deeb","year":"2018","unstructured":".Deeb A, Elfatih A. Could alerting physicians for low alkaline phosphatase levels be helpful in early diagnosis of hypophosphatasia? J Clin Res Pediatr Endocrinol. 2018;10(1):19-24.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"3","key":"key20200408093659_B6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00198-015-3346-0","article-title":"Absence of recognition of low alkaline phosphatase level in a tertiary care hospital","volume":"27","author":"Maman","year":"2016","unstructured":".Maman E, Borderie D, Roux C, Briot K. Absence of recognition of low alkaline phosphatase level in a tertiary care hospital. Osteoporos Int. 2016;27(3):1251-54.","journal-title":"Osteoporos Int"},{"issue":"10","key":"key20200408093659_B7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","unstructured":".Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D,  et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904-13.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20200408093659_B8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jbmr.3075","article-title":"Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges","volume":"32","author":"Whyte","year":"2017","unstructured":".Whyte MP. Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res. 2017;32(4):667-75.","journal-title":"J Bone Miner Res"},{"key":"key20200408093659_B9","article-title":"The tissue nonspecific alkaline phosphatase gene mutations database","author":"Mornet","year":"2018","unstructured":".Mornet E. The tissue nonspecific alkaline phosphatase gene mutations database. Versailles-Saint Quentin en Yvelines (France); 2018. Dispon\u00edvel em: http:\/\/www.sesep.uvsq.fr\/03_hypo_mutations.php.","journal-title":"Versailles-Saint Quentin en Yvelines"},{"issue":"5","key":"key20200408093659_B10","doi-asserted-by":"crossref","first-page":"5S61","DOI":"10.1016\/S0929-693X(18)30016-2","article-title":"Perinatal and infantile hypophosphatasia: clinical features and treatment","volume":"24","author":"Baujat","year":"2017","unstructured":".Baujat G, Michot C, Le Quan Sang KH, Cormier-Daire V. Perinatal and infantile hypophosphatasia: clinical features and treatment. Arch Pediatr.2017;24(5S2):5S61-5S65.","journal-title":"Arch Pediatr"},{"issue":"1","key":"key20200408093659_B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.14366\/usg.15008","article-title":"Prenatal diagnosis of hypophosphatasia congenita using ultrasonography","volume":"35","author":"Guguloth","year":"2016","unstructured":".Guguloth A, Aswani Y, Anandpara KM. Prenatal diagnosis of hypophosphatasia congenita using ultrasonography. Ultrasonography. 2016;35(1):83-6.","journal-title":"Ultrasonography"},{"issue":"5","key":"key20200408093659_B12","doi-asserted-by":"crossref","first-page":"5S89","DOI":"10.1016\/S0929-693X(18)30022-8","article-title":"Craniosynostosis and hypophosphatasia","volume":"24","author":"Di Rocco","year":"2017","unstructured":".Di Rocco F, Baujat G, Cormier-Daire V, Rothenbuhler A, Linglart A. Craniosynostosis and hypophosphatasia. Arch Pediatr. 2017;24(5S2):5S89-5S92.","journal-title":"Arch Pediatr"},{"issue":"5","key":"key20200408093659_B13","doi-asserted-by":"crossref","first-page":"5S66","DOI":"10.1016\/S0929-693X(18)30017-4","article-title":"Hypophosphatasia in children and adolescents: clinical features and treatment","volume":"24","author":"Rothenbuhler","year":"2017","unstructured":".Rothenbuhler A, Linglart A. Hypophosphatasia in children and adolescents: clinical features and treatment. Arch Pediatr. 2017;24(5S2):5S66-5S70.","journal-title":"Arch Pediatr"},{"issue":"5","key":"key20200408093659_B14","doi-asserted-by":"crossref","first-page":"5S74","DOI":"10.1016\/S0929-693X(18)30019-8","article-title":"Hypophosphatasia: the contribution of imaging","volume":"24","author":"Linglart","year":"2017","unstructured":".Linglart A, Salles JP. Hypophosphatasia: the contribution of imaging. Arch Pediatr. 2017;24(5S2):5S74-5S79.","journal-title":"Arch Pediatr"},{"issue":"9","key":"key20200408093659_B15","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00198-017-4087-z","article-title":"Clinical, radiographic and biochemical characteristics of adult hypophosphatasia","volume":"28","author":"Schmidt","year":"2017","unstructured":".Schmidt T, Mussawy H, Rolvien T, Hawellek T, Hubert J, R\u00fcther W,  et al. Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int. 2017;28(9):2653-62.","journal-title":"Osteoporos Int"},{"issue":"4","key":"key20200408093659_B16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2110","article-title":"Calcific periarthritis as the only clinical manifestation of hypophosphatasia in middle-aged sisters","volume":"29","author":"Gua\u00f1abens","year":"2014","unstructured":".Gua\u00f1abens N, Mumm S, M\u00f6ller I, Gonz\u00e1lez-Roca E, Peris P, Demertzis JL,  et al. Calcific periarthritis as the only clinical manifestation of hypophosphatasia in middle-aged sisters. J Bone Miner Res. 2014;29(4):929-34.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20200408093659_B17","doi-asserted-by":"crossref","first-page":"5S80","DOI":"10.1016\/S0929-693X(18)30020-4","article-title":"Hypophosphatasia: oral cavity and dental disorders","volume":"24","author":"Bloch-Zupan","year":"2017","unstructured":".Bloch-Zupan A, Vaysse F. Hypophosphatasia: oral cavity and dental disorders. Arch Pediatr. 2017;24(5S2):5S80-5S84.","journal-title":"Arch Pediatr"},{"issue":"48","key":"key20200408093659_B18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013210","article-title":"Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: Case report","volume":"97","author":"Freitas","year":"2018","unstructured":".Freitas TQ, Franco AS, Pereira RMR. Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: Case report. Medicine (Baltimore). 2018 Nov;97(48):e13210.","journal-title":"Medicine"},{"issue":"5","key":"key20200408093659_B19","doi-asserted-by":"crossref","first-page":"5S51","DOI":"10.1016\/S0929-693X(18)30014-9","article-title":"Genetics of hypophosphatasia","volume":"24","author":"Mornet","year":"2017","unstructured":".Mornet E. Genetics of hypophosphatasia. Arch Pediatr. 2017;24(5S2):5S51-5S56.","journal-title":"Arch Pediatr"},{"issue":"2","key":"key20200408093659_B20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40265-015-0535-2","article-title":"Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia","volume":"76","author":"Scott","year":"2016","unstructured":".Scott LJ. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia. Drugs. 2016;76(2):255-62.","journal-title":"Drugs"},{"issue":"1","key":"key20200408093659_B21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","unstructured":".Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A,  et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334-42.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"key20200408093659_B22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00198-018-4613-7","article-title":"Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia","volume":"29","author":"Bowden","year":"2018","unstructured":".Bowden SA, Adler BH. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia. Osteoporos Int. 2018;29(9):2155-56.","journal-title":"Osteoporos Int"},{"issue":"1","key":"key20200408093659_B23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cen.13343","article-title":"Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial","volume":"87","author":"Kitaoka","year":"2017","unstructured":".Kitaoka T, Tajima T, Nagasaki K. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial. Clin Endocrinol (Oxf). 2017;87(1): 10-9.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"key20200408093659_B24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/jbmr.1565","article-title":"\u201cAtypical femoral fractures\u201d during bisphosphonate exposure in adult hypophosphatasia","volume":"27","author":"Sutton","year":"2012","unstructured":".Sutton RA, Mumm S, Coburn SP, Ericson KL, Whyte MP. \u201cAtypical femoral fractures\u201d during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res. 2012;27(5):987-94.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"key20200408093659_B25","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: a Phase 2 Open-Label Study","volume":"104","author":"Hofmann","year":"2019","unstructured":".Hofmann CE, Harmatz P, Vockley J, H\u00f6gler W, Nakayama H, Bishop N,  et al. Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: a Phase 2 Open-Label Study. J Clin Endocrinol Metab. 2019;104(7):2735-47.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T13:37:19Z","timestamp":1586353039000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972020005002204&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":25,"alternative-id":["10.20945\/2359-3997000000222"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000222","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}